lansoprazole has been researched along with Ulcer in 13 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
Excerpt | Relevance | Reference |
---|---|---|
"There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD." | 9.41 | Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023) |
"To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 8.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
"The objective of this study was to formulate and evaluate the lansoprazole (LPZ)-loaded microparticles to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease (GERD)." | 7.79 | A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation. ( Alai, M; Lin, WJ, 2013) |
"The effect of lansoprazole, a proton pump inhibitor (PPI), on indomethacin-induced small intestinal ulceration was examined in rats, particularly in relation to heme oxygenase (HO)-1." | 7.76 | Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1. ( Amagase, K; Higuchi, K; Kakimoto, K; Kato, S; Murano, M; Nishio, H; Takeuchi, K; Tokioka, S; Umegaki, E; Yoda, Y, 2010) |
"There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD." | 5.41 | Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023) |
"A combination package containing delayed-release capsules of the proton pump inhibitor lansoprazole (15 mg once daily) and tablets of the NSAID naproxen (375 or 500 mg twice daily) has been approved for reducing the risk of NSAID-associated gastric ulcers in NSAID-requiring patients with a documented history of gastric ulcer." | 4.82 | Delayed-release lansoprazole plus naproxen. ( Curran, MP; Wellington, K, 2004) |
"To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 4.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
"The objective of this study was to formulate and evaluate the lansoprazole (LPZ)-loaded microparticles to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease (GERD)." | 3.79 | A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation. ( Alai, M; Lin, WJ, 2013) |
"The effect of lansoprazole, a proton pump inhibitor (PPI), on indomethacin-induced small intestinal ulceration was examined in rats, particularly in relation to heme oxygenase (HO)-1." | 3.76 | Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1. ( Amagase, K; Higuchi, K; Kakimoto, K; Kato, S; Murano, M; Nishio, H; Takeuchi, K; Tokioka, S; Umegaki, E; Yoda, Y, 2010) |
"Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0." | 2.68 | Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997) |
"Lansoprazole 30 mg was started." | 1.33 | Pill esophagitis caused by telithromycin: a case report. ( Büyükberber, M; Demirci, F; Gülşen, MT; Kis, C; Koruk, M; Savaş, MC, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (15.38) | 18.2507 |
2000's | 6 (46.15) | 29.6817 |
2010's | 3 (23.08) | 24.3611 |
2020's | 2 (15.38) | 2.80 |
Authors | Studies |
---|---|
Miao, T | 1 |
Zhang, Y | 1 |
Bai, L | 1 |
Yang, X | 1 |
Wen, X | 1 |
Gao, N | 2 |
Yan, S | 2 |
Chen, B | 2 |
Kitagawa, T | 1 |
Sato, K | 1 |
Yokouchi, Y | 1 |
Tominaga, K | 1 |
Ito, S | 1 |
Maetani, I | 1 |
Yoda, Y | 1 |
Amagase, K | 1 |
Kato, S | 1 |
Tokioka, S | 1 |
Murano, M | 1 |
Kakimoto, K | 1 |
Nishio, H | 1 |
Umegaki, E | 1 |
Takeuchi, K | 1 |
Higuchi, K | 1 |
Alai, M | 1 |
Lin, WJ | 1 |
Guda, N | 1 |
Vakil, N | 1 |
Sawhney, MS | 1 |
Nelson, DB | 1 |
Curran, MP | 1 |
Wellington, K | 1 |
Büyükberber, M | 1 |
Demirci, F | 1 |
Savaş, MC | 1 |
Kis, C | 1 |
Gülşen, MT | 1 |
Koruk, M | 1 |
Sontag, SJ | 1 |
Kogut, DG | 1 |
Fleischmann, R | 1 |
Campbell, DR | 1 |
Richter, J | 1 |
Robinson, M | 1 |
McFarland, M | 1 |
Sabesin, S | 1 |
Lehman, GA | 1 |
Castell, D | 1 |
Kobayashi, S | 1 |
Kawabe, N | 1 |
Miyata, F | 1 |
Ito, H | 1 |
Kazumiya, H | 1 |
Murase, K | 1 |
Kurokawa, S | 1 |
Fujishima, K | 1 |
Stolte, M | 1 |
Vieth, M | 1 |
Schmitz, JM | 1 |
Alexandridis, T | 1 |
Seifert, E | 1 |
Byrne, M | 1 |
Sheehan, K | 1 |
Kay, E | 1 |
Patchett, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | minutes (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
Intervention | Minutes (Mean) | |||
---|---|---|---|---|
postnaprosyn baseline | week 1 | week 2 | Week 4 | |
Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | awakenings (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | minutes (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
2 reviews available for lansoprazole and Ulcer
Article | Year |
---|---|
Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis.
Topics: Endoscopic Mucosal Resection; Humans; Lansoprazole; Proton Pump Inhibitors; Stomach Neoplasms; Stoma | 2023 |
Delayed-release lansoprazole plus naproxen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2004 |
2 trials available for lansoprazole and Ulcer
Article | Year |
---|---|
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Meth | 1997 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
9 other studies available for lansoprazole and Ulcer
Article | Year |
---|---|
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
A case of lansoprazole-associated collagenous colitis with longitudinal ulcer.
Topics: Aged; Anti-Ulcer Agents; Biopsy; Colitis, Collagenous; Colitis, Ischemic; Colon; Colonic Diseases; C | 2013 |
Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colony Co | 2010 |
A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation.
Topics: Acids; Acrylic Resins; Animals; Anti-Ulcer Agents; Delayed-Action Preparations; Gastroesophageal Ref | 2013 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru | 2003 |
Pill esophagitis caused by telithromycin: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Endoscopy, | 2006 |
[A case of Behcet's syndrome associated with esophageal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents; Anti-Ulcer Agents; Behcet | 1998 |
Symptomatic ulceration of an acid-producing oesophageal inlet patch colonized by helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Endoscopes; Esophagus; Helicobact | 2002 |